 Maverix had a busy year in 2021, increasing its exposure to Omolon and doing a meaningful deal with Auramet, which will boost annual GEO sales by more than 12. Meanwhile, the company has seen lots of progress by its operators at both producing royalties and development-stage royalties, with its portfolio getting stronger with no money spent by Maverix. 